Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin | Zendy

Dragoş Vinereanu | Zendy; Renato D. Lópes | Zendy; Hillary Mulder | Zendy; Bernard J. Gersh | Zendy; Michael G. Hanna | Zendy; Pedro Gabriel Melo de Barros e Silva | Zendy; Dan Atar | Zendy; Lars Wallentin | Zendy; Christopher B. Granger | Zendy; John H. Alexander | Zendy

Open Access

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin

Author(s) -

Dragoş Vinereanu,

Renato D. Lópes,

Hillary Mulder,

Bernard J. Gersh,

Michael G. Hanna,

Pedro Gabriel Melo de Barros e Silva,

Dan Atar,

Lars Wallentin,

Christopher B. Granger,

John H. Alexander

Publication year - 2017

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.117.017574

Subject(s) - medicine , apixaban , atrial fibrillation , cardiology , hazard ratio , stroke (engine) , warfarin , thrombus , confidence interval , embolism , myocardial infarction , left ventricular thrombus , rivaroxaban , mechanical engineering , engineering

Few data exist on the long-term outcomes of patients with spontaneous echo contrast (SEC), left atrial/left atrial appendage (LA/LAA) thrombus, and complex aortic plaque (CAP), in patients with atrial fibrillation receiving oral anticoagulation. We explored the relationship between these 3 echocardiographic findings and clinical outcomes, and the comparative efficacy and safety of apixaban and warfarin for each finding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research